Clinical trials: Aromatase Inhibitor
Breast Cancer
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
- Trial name
- NCT05549505
- Testing
- ARV-471, Anastrozole, Surgical resection of breast tumor
- Where
- 49 sites in United States, Georgia and 2 more
- Volunteers
- 152 people
- Sponsor
- Arvinas Inc.
Patients With Early Breast Cancer Who Initiating Adjuvant Aromatase Inhibitor
Tailored Exercise to Reduce Aromatase Inhibitor Associated Musculoskeletal Symptoms
A randomized controlled study evaluating effect of tailored exercise compared to routine practice as a preventive measure of aromatase inhibitor associated musculoskeletal related symptoms in early breast cancer patients
- Trial name
- TAILOR-Ex (NCT07448558)
- Testing
- tailored exercise
- Where
- Thailand
- Volunteers
- 206 people
- Sponsor
- Mahidol University
Breast Cancer
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
The primary purpose of this study is to help answer the following research question: whether enzastaurin given together with fulvestrant can help participants who have breast cancer and make the tumor smaller or disappear and for…
- Trial name
- NCT00451555
- Testing
- enzastaurin, fulvestrant
- Where
- 21 sites in France, Germany and 3 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Joint Pain, Breast Cancer
Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy
For post-menopausal women diagnosed with hormone-receptor positive breast cancer tumors, aromatase inhibitors (AIs) are the standard adjuvant hormone treatment to prolong disease-free survival and time-to-recurrence.
- Trial name
- NCT01900418
- Testing
- Walk with Ease
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- University of North Carolina, Chapel Hill
Breast Cancer
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
This study explores how aromatase inhibitor therapy affects risk factors for heart disease in postmenopausal women with breast cancer.
- Trial name
- Silhouette (NCT01080170)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Breast Cancer
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors
The goal of this research study is to learn more about what it is like for patients with breast cancer to receive treatment with the drug anastrozole.
- Trial name
- NCT00738998
- Testing
- Questionnaire, Phone Calls
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Metastatic, Metastatic Breast Cancer
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II
The goal of this clinical trial is to assess Stereotactic Ablative Radiotherapy (SABR) as a method to delay a change in systemic therapy in patients with oligoprogressive ER-positive, HER2-negative advanced breast cancer.
- Trial name
- AVATARII (NCT06882499)
- Testing
- Stereotactic Ablative Radiotherapy, Physician's choice of systemic treatment
- Volunteers
- 74 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00754845
- Testing
- letrozole
- Where
- 43 sites in Canada, United Kingdom
- Volunteers
- 1,918 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI
500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI
- Trial name
- NCT03695341
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
The course of the disease in female patients with metastatic mammary carcinoma can vary greatly. In this connection, the individual prognosis depends on a complex interaction of tumor- and patient-related factors.
- Trial name
- NCT00241046
- Testing
- Letrozole
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
Pfizer's innovative drug palbociclib (trade name: Ibrance®) got China National Drug Administration (CNDA) approval on July 31, 2018.
- Trial name
- NCT04047758
- Testing
- Palbociclib + Letrozole, Letrozole
- Where
- 3 sites in China
- Volunteers
- 420 people
- Sponsor
- Shengjing Hospital
Breast Neoplasms, Medication Adherence
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
Background: In women with hormone receptor positive (HR+) breast cancer, adjuvant endocrine therapy (AET) is associated with a significant survival advantage.
- Trial name
- NCT02876848
- Testing
- OPTIMUM e-health tool
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Breast Cancer
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
This was a Phase II, multicenter, open-label, three-cohort, non-comparative study of alpelisib plus endocrine therapy (either fulvestrant or letrozole) in subjects (pre- and post-menopausal women and men) with HR-positive…
- Trial name
- BYLieve (NCT03056755)
- Testing
- Alpelisib, Fulvestrant, Letrozole
- Where
- 94 sites in United States, Argentina and 17 more
- Volunteers
- 383 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Invasive Breast Cancer
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.
- Trial name
- NCT03219476
- Testing
- Anastrozole, Letrozole, Exemestane
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer
CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer
Breast cancer is the most common form of cancer among women. For patients candidated for adjuvant chemotherapy and endocrine therapy the optimal timing for their has not been clearly defined yet.
- Trial name
- GIM10-CONSENT (NCT02918084)
- Testing
- Anastrozole or Letrozole or Exemestane
- Where
- 74 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer, Arthralgia
A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors and Tamoxifen
The Logribmet study is a prospective study that evaluate grip strength changes in both hands of postmenopausal women with breast cancer receiving treatment with tamoxifen or an aromatase inhibitor.
- Trial name
- LOGRIBMET (NCT01223833)
- Where
- Belgium
- Volunteers
- 296 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Ectopic Pregnancy
The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy
The aim of this study is to : 1. Use of the aromatase inhibitor( letrozole) for the treatment of ectopic pregnancy compared to methotrexate. 2.
- Trial name
- NCT04308343
- Testing
- Methotrexate, Letrozole, cetrotide
- Volunteers
- 120 people
- Sponsor
- Assiut University
Vasomotor Symptoms (VMS)
Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor
This is a Phase 2 proof-of-concept (POC) study designed to determine the effectiveness of Q-122 for the treatment of Vasomotor Symptoms (VMS) versus placebo.
- Trial name
- NCT03518138
- Testing
- Q-122
- Where
- 18 sites in United States, Australia and 1 more
- Volunteers
- 132 people
- Sponsor
- Que Oncology
Arthralgia
Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer
Aromatase inhibitors have been used to treat hormone receptor positive breast cancer women in menopause, but side effects, such as joint pain, would affect their qualities of life.
- Trial name
- NCT05264649
- Testing
- acupuncture, Guizhi-Shaoyao-Zhimu decoction
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- Show Chwan Memorial Hospital
Musculoskeletal Syndrome
A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)
Aromatase inhibitors (AIs) are commonly used for post-menopausal women with hormone-positive breast cancer. Compared to tamoxifen, AIs improve breast cancer recurrence rates and lower 10-year breast cancer mortality.
- Trial name
- NCT05935891
- Testing
- CBD-dominant, THC dominant
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota